

Selected Clinical Trials – Currently Open

(Updated May 2018)

Most clinical trials limit enrollment to only ACC patients with advanced disease (many measurable tumors). Increasingly, only patients with progressive disease (growing tumors) are being included in ACC studies. Each patient's decision to enter a clinical trial is very personal and will be based on a blend of the disease's progression, the treatment's anticipated effectiveness, the patient's tolerance of side effects, financial constraints and travel limitations. Each situation is unique and should be discussed with a knowledgeable physician.

Table 1. Clinical Trials Recruiting ACC and/or Salivary Gland Cancer Patients

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
Pembrolizumab and Docetaxel (for salivary gland cancer patients)	PD-1 Immunotherapy	University of Chicago	Chicago, IL, USA	Solid	View	Tanguy Y. Seiwert 773-834-7424 tseiwert@medicine.bsd.uchicago.edu
Pembrolizumab +/- Radiation (for ACC patients)	PD-1 Immunotherapy	Dana Farber Cancer Institute	Boston, MA, USA	Solid	View	Nicole Chau, MD 1-617-632-3090 nicole_chau@dfci.harvard.edu
Nivolumab and Ipilimumab (for salivary gland cancer patients)	PD-1 and CTLA-4 Immunotherapy	Memorial Sloan Kettering	New York, NY, USA	Solid	View	Alan Ho, MD, PhD 1-646-888-4235
Nivolumab and Ipilimumab (for salivary gland cancer patients)	PD-1 And CTLA-4 Immunotherapy	Northwestern University	Chicago, IL, USA	Solid	View	Maria Matsangou, MD 1-312-695-6182
PSMA-PET Imaging (for ACC patients)	PSMA	Radboud University	Nijmegen, Netherlands	Solid	View	Carla ML van Herpen, MD, PhD Carla.vanHerpen@radboudumc.nl Wim van Boxtel, MD +31625034690 Wim.vanBoxtel@radboudumc.nl
Chidamide (for ACC patients)	HDAC	Chinese Academy of Medical Sciences	Beijing, China	Solid	View	Mei Dong +86-10-87788130 Dongmei030224@163.com

Table 2. Selected Phase I Clinical Trials

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
APG-115	MDM2	Ascentage	Grand Rapids, MI San Antonio, TX	Solid	View	Yifan Zhai, MD, PhD 240-505-6608 yzhai@ascentagepharma.com
HDM201	MDM2	Novartis	USA (MA, NY), France, Germany, Japan, Netherlands, Singapore, Spain, Taiwan	Solid	View	Novartis Pharmaceuticals 1-888-669-6682 +41613241111
DS-3032b	MDM2	Daiichi Sankyo	Detroit, MI New York, NY Nashville, TN Houston, TX	Solid	View	Andrew Ruwe, PhD 1-513-579-9911 ext 2353 a.ruwe@medpace.com

Table 3. Selected Phase I Clinical Trials of NOTCH inhibitors
(for patients with NOTCH alterations or activation)

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
LY3039478	NOTCH	Eli Lilly	USA (CA, FL, MI, TX), Denmark, France, Spain	Strong	View	1-877-285-4559 or 1-317-615-4559

Table 4. “Basket” Clinical Trials Incorporating Tumor Profiling

Compound	Target(s)	Institution(s)	Location(s)	Scientific Rationale	Info Link	Contact
NCI-MATCH	Multiple targets	National Cancer Institute	Over 1,000 locations in USA	Solid	View	View Info Link for details on each site
NCI-DART (Nivolumab and Ipilimumab for NCI-MATCH patients with rare tumors without targetable alterations)	PD-1 and CTLA-4 Immunotherapy	National Cancer Institute	Over 600 locations in USA	Solid	View	View Info Link for details on each site
ASCO TAPUR	Multiple targets	American Society of Clinical Oncology	USA (MI, NC; eventually national)	Solid	View	Pam Mangat, MS pam.mangat@asco.org
Drug Therapies for Salivary Gland Cancers Based on Testing of Genes (for salivary gland cancer patients; only Canadian patients are eligible)	Multiple targets	University Health Network, Toronto	Toronto, Ontario, Canada	Solid	View	Albiruni Razak, M.D. 1-416-946-4501 ext 3428